Navigation Links
American Oriental Bioengineering Reports Second Quarter 2011 Financial Results
Date:8/9/2011

NEW YORK, Aug. 9, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), (the "Company" or "AOB"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced financial results for the second quarter ended June 30, 2011.

Second Quarter 2011 Financial PerformanceIn the second quarter of 2011, revenue decreased to $54.1 million from $77.3 million in the same period of 2010.

  • The Company generated revenue of $50.3 million from its manufacturing business in the second quarter of 2011 compared with $73.7 million in the prior year period. Revenue from pharmaceutical products decreased to $40.7 million from $63.8 million in the prior year period. Nutraceutical products generated revenue of approximately $9.5 million in the second quarter of 2011, compared to $9.9 million in the prior year period. We decreased the manufacturing of certain generic drugs strategically shifted the products mix toward higher-margin products from lower margin products in order to minimize the impact from the increased cost of certain raw materials and the continuing government price cut on certain products.
  • The Company generated $3.8 million from its distribution business, Nuo Hua, in the second quarter of 2011, an increase of 5.2% from $3.6 million in the prior year period.

  • Gross profit in the second quarter of 2011 was $25.8 million compared to $39.8 million in the second quarter of 2010. Gross margin was 47.8% compared to 51.5% in the prior year period. The margin pressure was mainly caused by the increased costs of certain raw materials and newly levied urban construction and maintenance tax and educational surcharge to foreign invested companies in China since December, 2010.

    Operating
    '/>"/>

    SOURCE American Oriental Bioengineering, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems
    2. American Pacific to Release Financial Results and Hold Fiscal 2011 Third Quarter Investor Teleconference
    3. American Regent, Inc. Initiates Voluntary Recall of Seventeen Lots of Vasopressin Injection, USP, Multiple Dose Vials due to Sub-Potency
    4. Grifols Announces New North American Commercial Operations Organization
    5. Siemens Partners with American Cancer Society to Make Strides Against Breast Cancer
    6. Stigma Remains a Significant Barrier to Routine HIV Testing by African-American Physicians, Survey Finds
    7. Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels
    8. Survey Finds More Than One in Three Americans Have Been Personally Affected By Infections Resulting From a Hospital Stay
    9. Waters Showcases ACQUITY UltraPerformance LC and Mass Spectrometry (UPLC/MS) Tools for Increasing Laboratory Efficiency at the American Association for Clinical Chemistry Annual Meeting
    10. North American External Defibrillator Market
    11. American College of Surgeons Announces Goal to Enlist 1,000 Hospitals to its National Surgical Quality Improvement Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... YORK , Aug. 20, 2014 ... new market research report is available ... Market for Hospital-Acquired Infection Control (Sterilization, ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... healthcare-associated infections (HAIs), demand has increased ...
    (Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: The Impact of Healthcare ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html The ... is complex legislation that affects virtually every aspect ... are beginning to take effect now. IVD manufacturers ...
    (Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... France, Key Trends and Opportunities to 2018 ... Synopsis The report provides in depth ... French personal accident and health insurance segment, ...
    Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
    ... - Biovest,International, Inc. (OTCBB: BVTI), a majority owned ... 2007 blinded interim data from the start of ... for Non-Hodgkin's,lymphoma (NHL) from September 2000 through June ... data that has been made available,to the Company ...
    ... at the 11th International Myeloma Workshop -, NORTH ... -- The International Myeloma Foundation (IMF) --,supporting research ... families, researchers and physicians -- today,said that updated ... Greece demonstrate improved survival for a wide,range of ...
    Cached Medicine Technology:Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4
    (Date:8/20/2014)... In its latest blog post, A Forever ... gets clients off to a great start and gives them ... highlighting an important and possibly life-changing – perhaps even life-saving ... to understand the insidious nature of drug abuse: it doesn’t ... abuse targets a certain socioeconomic group, such as inner-city youth ...
    (Date:8/20/2014)... CA (PRWEB) August 20, 2014 The ... that Munira Lokhandwala, DDS, FAGD of Starbrite Dental in ... the AGD 2014 Annual Meeting & Exhibits, which took ... Award is presented to dentists who seek to provide ... profession. To earn this prestigious honor, Dr. Lokhandwala completed ...
    (Date:8/20/2014)... straight women are much more likely to seek treatment ... new study finds. Researchers examined data gathered from ... took part in polls in 2002 and 2006-2010, conducted ... study. In the first poll, 13 percent of ... This ranged from getting advice from doctors to more ...
    (Date:8/20/2014)... August 20, 2014 Transrectal ultrasound guided biopsy is ... reports have suggested that the number of risks associated ... population-based study, Swedish researchers found that six percent of ... tract infection within 30 days after having a prostate ... five years, reports The Journal of Urology . ...
    (Date:8/20/2014)... August 20, 2014 According to an ... August 7 in the multicounty litigation (MCL) case pending ... DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly 350 ... been dismissed without prejudice. The cases enumerated in the ... being resolved.” The Rottenstein Law Group LLP, a national ...
    Breaking Medicine News(10 mins):Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Fremont Dentist Receives Prestigious AGD Fellowship Award 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2Health News:Severe infections with hospitalization after prostate biopsy rising in Sweden 2Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2
    ... disparities in longevity still tied to geography, race and income, ... who smoke, have high blood pressure, high blood sugar and ... average of four years, a new study finds. , In ... while women could be shaving 4.1 years off their lives, ...
    ... ... of the survivors of the earthquake in Haiti. The Grand Canyon University community has donated ... disaster struck on January 12, 2010. , ... Phoenix, AZ (PRWEB) March 23, 2010 -- Grand Canyon University,s Compassion ...
    ... ... expanded its continuum of care with a new licensed assisted living center. Under the direction ... a week. The center,s dedicated nurses and aides provide care and support to residents, helping ... ...
    ... a Preferred Partner to Genesis Rehab Services. , ... , , ... ... Being named a Preferred Partner means that Genesis Rehab ...
    ... BRISBANE, Calif. , March 23 InterMune, Inc. ... Authorization Application (MAA), submitted on March 2 seeking ... (IPF) in adults, was validated by the European Medicines Agency ... the application is complete and that the review process will ...
    ... ... Software-as-a-Service Model , ... (PRWEB) March 23, 2010 -- Healthmaster®, the worldwide leader in electronic medical record software ... their HealthOffice® Software-as-a-Service (Saas) platform in Online Tech’s SAS-70 certified data centers . ...
    Cached Medicine News:Health News:Healthy Living Adds Years to Life 2Health News:Healthy Living Adds Years to Life 3Health News:Healthy Living Adds Years to Life 4Health News:Grand Canyon University (GCU) Creates Special Relief Fund and Raises Money for Haiti Earthquake Survivors 2Health News:Classic Residence by Hyatt at Teaneck Opens Licensed Assisted Living Center 2Health News:ReGear Life Sciences Named Preferred Partner to Genesis Rehab Services 2Health News:ReGear Life Sciences Named Preferred Partner to Genesis Rehab Services 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 2Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 4Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 6Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 7Health News:Online Tech and Healthmaster Sign SaaS Hosting Agreement 2Health News:Online Tech and Healthmaster Sign SaaS Hosting Agreement 3
    The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
    ... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
    ... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
    The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
    Medicine Products: